Movement Disorders

β-2 Adrenergic Agonists Linked to α-synuclein Transcription and Risk of PD

β-2 Adrenergic Agonists Linked to α-synuclein Transcription and Risk of PD

β-2 adrenergic agonists might be able to fight Parkinson's disease.

Parkinson's: Sleep Disturbances Affect Clinical Motor Subtypes, Disability

Parkinson's: Sleep Disturbances Affect Clinical Motor Subtypes, Disability

By

Patients with postural instability and gait disturbances had worse sleep scores than those with tremor-dominant Parkinson's.

MRI in Parkinson's Disease: Expanding Usability for Better Diagnostics

MRI in Parkinson's Disease: Expanding Usability for Better Diagnostics

By

MRI may be used to identify Parkinson disease biomarkers that can inform diagnosis, track disease progression, and elucidate the neurobiological underpinnings of symptoms.

Increased Mortality in Parkinson's Disease Linked to Low Antidepressant Adherence

Increased Mortality in Parkinson's Disease Linked to Low Antidepressant Adherence

By

Given the prevalence of depression in Parkinson's disease and the effectiveness of antidepressants, health care providers should promote adherence in clinical practice.

Age, Gender, and Cognition Predict Weight Loss in Parkinson's Disease

Age, Gender, and Cognition Predict Weight Loss in Parkinson's Disease

By

Enrollment of patients with only early Parkinson's disease in this trial prevents generalization of the study's findings across the entire Parkinson's population.

Parkinson's, REM Sleep Disorder Combination Linked to Cognitive Decline

Parkinson's, REM Sleep Disorder Combination Linked to Cognitive Decline

By

Patients with both Parkinson's and rapid eye movement sleep behavior disorder were much more likely to experience mild cognitive impairment.

Levodopa-Induced Euphoria May Drive Addictions, Behavior in Parkinson's

Levodopa-Induced Euphoria May Drive Addictions, Behavior in Parkinson's

By

Patients taking levodopa therapy may experience neuropsychiatric fluctuations characterized by changes in mood, motivation, and anxiety while in ON and OFF states of drug therapy.

Remote Neurological Care a Feasible Option for Parkinson's Disease

Remote Neurological Care a Feasible Option for Parkinson's Disease

For patient's with Parkinson's disease, virtual house calls from neurologists may be of interest.

Patients With Intellectual Disability More Susceptible to Movement Side Effects of Antipsychotics

Patients With Intellectual Disability More Susceptible to Movement Side Effects of Antipsychotics

By

Incidence of neuroleptic malignant syndrome, akathisia, and parkinsonism was higher in the ID group.

Austedo Wins Second Indication for Tardive Dyskinesia

Austedo Wins Second Indication for Tardive Dyskinesia

By

Austedo was previously approved for the treatment of chorea in Huntington's disease.

Tardive Dyskinesia: Experts Weigh in on New Treatments, Ongoing Challenges

Tardive Dyskinesia: Experts Weigh in on New Treatments, Ongoing Challenges

By

The main challenge is to determine when treating tardive dyskinesia with any pharmacological agent would provide a net benefit.

Exenatide Presents Exciting Therapeutic Possibilities for Parkinson's Disease

Exenatide Presents Exciting Therapeutic Possibilities for Parkinson's Disease

By

In a disease where there have been few therapeutic developments since dopamine, exenatide offers a promising new channel of exploration.

FDA Approves Parkinson's Dyskinesia Treatment

FDA Approves Parkinson's Dyskinesia Treatment

By

Gocovri is the first treatment for dyskinesia approved for patients with Parkinson's disease who are receiving levodopa therapy.

Algorithm Accurately Predicts Cognitive Decline in Parkinson's Disease

Algorithm Accurately Predicts Cognitive Decline in Parkinson's Disease

By

Patients with the highest predictive scores faced a greater risk of developing cognitive impairment and dementia in the first 10 years after disease onset.

Mislabeled Parkinson's Drug Recalled

Mislabeled Parkinson's Drug Recalled

By

Cyclobenzaprine HCl may potentially lead to life-threatening serotonin syndrome when the drug is taken in combination with selective serotonin reuptake inhibitors.

Daily Creatine Fails to Show Benefits in Early Huntington's Disease

Daily Creatine Fails to Show Benefits in Early Huntington's Disease

By

Despite promising results in earlier studies, researchers found no benefit for creatine in patients with early Huntington's disease.

Ocular Tremor in Parkinson's Disease: Inherent or Compensatory?

Ocular Tremor in Parkinson's Disease: Inherent or Compensatory?

By

Debate continues as to whether ocular tremor represents a clinical marker of Parkinson's disease or a compensatory movement related to other bodily tremors.

Parkinson's, ALS Risk Increased in White-Collar Workers

Parkinson's, ALS Risk Increased in White-Collar Workers

There is a higher risk of death from Parkinson's disease or ALS in white collar workers.

Vision Changes May Precede Parkinson's Disease

Vision Changes May Precede Parkinson's Disease

People who experience changes in vision may be at risk for Parkinson's disease.

Parkinson's Patients May Face Greater Risk of Melanoma

Parkinson's Patients May Face Greater Risk of Melanoma

There is a 4 times greater risk of developing melanoma in Parkinson's disease, and vice versa.

Adjunct Therapy for Parkinson's Now Available

Adjunct Therapy for Parkinson's Now Available

By

Xadago tablets have been launched as add-on therapy for Parkinson's disease.

Evaluating the Effects of Treatment Conversion for Huntington's Chorea

Evaluating the Effects of Treatment Conversion for Huntington's Chorea

By

Overnight treatment conversion from tetrabenazine to deutetrabenazine in patients with HD was found to be safe.

Several Factors May Predict Cognitive Decline in Parkinson's Disease

Several Factors May Predict Cognitive Decline in Parkinson's Disease

By

Dopamine deficiency, decreases in cortical thickness and volume in certain areas of the brain was predictive of cognitive decline.

Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease

Extended-Release Amantadine Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease

By

Patients in the treatment group had improved ON and OFF times and no worsening of motor function.

Neurofilament Light Protein Shows Strong Potential as Biomarker for Huntington's Disease

Neurofilament Light Protein Shows Strong Potential as Biomarker for Huntington's Disease

By

Investigators examined blood plasma samples taken annually from a cohort of 201 huntingtin gene (HTT) carriers.

Identifying Prodromal Symptoms of Ataxia Type 2 for Early Intervention

Identifying Prodromal Symptoms of Ataxia Type 2 for Early Intervention

By

Investigators identified a series of prodromal signs that appear anywhere from 1 to 18 years before a clinical diagnosis of SCA2.

Risk for Death Significantly Increased in Patients With Synucleinopathies

Risk for Death Significantly Increased in Patients With Synucleinopathies

By

Patients with multiple system atrophy with parkinsonism face the greatest risk for death among synucleinopathies.

No Link Between Parkinson's, Overall Vagotomy

No Link Between Parkinson's, Overall Vagotomy

However, there is a trend toward lower risk of Parkinson's for patients with truncal vagotomy.

MRI-Guided Focused Ultrasound More Cost Effective Treatment for Essential Tremor

MRI-Guided Focused Ultrasound More Cost Effective Treatment for Essential Tremor

By

MRI-guided focused ultrasound thalamotomy is more effective than deep brain stimulation and significantly cheaper.

Electroconvulsive Therapy May Benefit Patients With Huntington's Disease

Electroconvulsive Therapy May Benefit Patients With Huntington's Disease

By

Electroconvulsive therapy might be safe and reliable therapy for treatment of psychiatric symptoms in patients with Huntington Disease

Sign Up for Free e-newsletters